Search results
Showing 3346 to 3360 of 7691 results
How voluntary and community sector (VCS) organisations can help us develop guidance
Support for organisations who contribute to developing our guidance
Resources to help organisations who want to help develop NICE guidance
When we're developing our guidance , we invite people with experience of a particular condition to share their views. This helps us understand the...
How people can have an impact on NICE guidance
People and communities - putting you at the heart of our work
We're committed to involving people who use services, carers and the public in the development of our guidance and other products. Your involvement...
Join Nice's Public Involvement Programme expert panel
With your help, we're improving outcomes for people who use the NHS and other public health and social care services. Find out how you can get...
People and communities - putting you at the heart of our work
We're committed to involving people who use services, carers and the public in the development of our guidance and other products. Your involvement...
There are a number of ways you can get involved in the development of our guidance.
Support for voluntary and community sector (VCS) organisations
Public involvement support for voluntary and community sector organisations
Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together...
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .